Pharmaceutical

China NMPA approves KeChow’s tunlametinib for melanoma

The China NMPA has granted approval to KeChow Pharma's tunlametinib for treating patients with NRAS-mutated advanced melanoma.

Mar 20, 2024 - 00:00
China NMPA approves KeChow’s tunlametinib for melanoma
The China NMPA has granted approval to KeChow Pharma's tunlametinib for treating patients with NRAS-mutated advanced melanoma.
Read the original article

Tags:

Previous Article

AstraZeneca to acquire radioconjugate biotech Fusion in $2.4bn deal

Next Article

Microsoft and NVIDIA expand collaboration in healthcare innovation

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: The Apellis eye drug rebound accelerates. This time, it’s a competitor falling behind

STAT+: The Apellis eye drug rebound accelerates. This t...

Sep 20, 2023

STAT+: Immunogen ovarian cancer drug shown to extend patients’ lives

STAT+: Immunogen ovarian cancer drug shown to extend pa...

May 3, 2023

SGNB-7H4V by Pfizer for Epithelial Ovarian Cancer: Likelihood of Approval

SGNB-7H4V by Pfizer for Epithelial Ovarian Cancer: Like...

Jun 20, 2024